Shimura Tatsuo, Shibata Masahiko, Kofunato Yasuhide, Okada Ryo, Ishigame Teruhide, Kimura Takashi, Kenjo Akira, Marubashi Shigeru
Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University, Fukushima, Japan.
Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Japan.
ANZ J Surg. 2018 Dec;88(12):1328-1332. doi: 10.1111/ans.14458. Epub 2018 Mar 13.
Although serum albumin has been reported to be useful as a prognostic biomarker for various malignancies, it is not suitable for prognosis of patients with hepatocellular carcinoma (HCC) due to impaired liver function. We aimed to determine whether serum transthyretin (TTR) level can be used as a novel prognostic biomarker.
Serum levels of TTR, as well as other nutritional and inflammatory parameters including angiogenic factors, were examined in 25 patients with HCC.
The serum TTR levels exhibited a statistically significant inverse correlation with interleukin-6 (r = -0.412, P = 0.041), and showed statistically significant correlations with retinol-binding protein (r = 0.919, P < 0.001) and albumin (r = 0.442, P = 0.027). The patients with TTR <11.4 mg/dL (P = 0.012), those with ≥T2 (P = 0.011) and those with a retention rate of indocyanine green after 15 min ≥15.5 (P = 0.037) showed poorer prognoses than the counterparts of each parameter. The TTR level <11.4 mg/dL (hazard ratio: 4.837, 95% confidence interval: 1.118-20.926, P = 0.035) and ≥T2 (hazard ratio: 5.011, 95% confidence interval: 1.243-20.203, P = 0.023) were independent prognostic factors of HCC patients.
Serum TTR measurement can be useful for predicting the prognosis of patients with HCC.
尽管血清白蛋白已被报道可作为多种恶性肿瘤的预后生物标志物，但由于肝功能受损，它不适用于肝细胞癌（HCC）患者的预后评估。我们旨在确定血清转甲状腺素蛋白（TTR）水平是否可作为一种新的预后生物标志物。
检测了25例HCC患者的血清TTR水平以及其他营养和炎症参数，包括血管生成因子。
血清TTR水平与白细胞介素-6呈统计学显著负相关（r = -0.412，P = 0.041），与视黄醇结合蛋白（r = 0.919，P < 0.001）和白蛋白（r = 0.442，P = 0.027）呈统计学显著正相关。TTR<11.4mg/dL的患者（P = 0.012）、T2期及以上的患者（P = 0.011）以及15分钟后吲哚菁绿滞留率≥15.5的患者（P = 0.037）的预后比各参数对应的患者更差。TTR水平<11.4mg/dL（风险比：4.837，95%置信区间：1.118 - 20.926，P = 0.035）和T2期及以上（风险比：5.011，95%置信区间：1.243 - 20.203，P = 0.023）是HCC患者的独立预后因素。
血清TTR检测可用于预测HCC患者的预后。
